leiomyomatosis


Also found in: Dictionary, Thesaurus, Encyclopedia.

lei·o·my·o·ma·to·sis

(lī'ō-mī'ō-mă-tō'sis),
The state of having multiple leiomyomas throughout the body.

leiomyomatosis

/leio·my·o·ma·to·sis/ (-mi″o-mah-to´sis) the occurrence of multiple leiomyomas throughout the body.

lei·o·my·o·ma·to·sis

(lī'ō-mī'ō-mă-tō'sis)
The state of having multiple leiomyomas throughout the body.
References in periodicals archive ?
MR and CT findings of leiomyomatosis peritonealis disseminata with emphasis on assisted reproductive technology as a risk factor.
Intravascular leiomyomatosis (IVL) is benign smooth muscle tumor within vessels, from intrauterine to the systemic veins8.
Utilization of luteinizing hormone-releasing hormone agonist in pulmonary leiomyomatosis.
Disseminated peritoneal leiomyomatosis is a rare benign entity in the differential diagnosis of multiple peritoneal masses with absence of ascites or constitutional symptoms, as are found in malignancies.
Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.
In a 2010 visit, she was evaluated for abnormal uterine bleeding (AUB) and was diagnosed with a myomatous uterus and genital leiomyomatosis.
In some cases, the hydropic change resulted in the now well-recognized peri-nodular hydropic pattern that may simulate IV leiomyomatosis.
Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology.
As previously mentioned, from a molecular standpoint, type 2 PRCC represents a heterogeneous group of molecularly distinct tumors and is currently considered to be a diagnosis of exclusion; other RCC entities with papillary architecture (ie, hereditary leiomyomatosis and RCC [HLRCC]-associated RCC, collecting duct carcinoma [CDC], among others) should be ruled out before rendering a diagnosis of type 2 PRCC.
Although the characterization and grouping of hRCC is evolving, we have limited our recommendations to those hRCC in which renal tumours are a prominent clinical presentation and various recommendations are available, including: von Hippel Lindau syndrome (VHL), hereditary papillary renal cell carcinoma (HPRC), hereditary leiomyomatosis renal cell carcinoma (HLRCC), Birt-Hogg-Dube syndrome (BHD), hereditary paragangliomas-pheochromocytoma syndromes (SDHB/SDHC/SDHD) and tuberous sclerosis complex (TSC).
intravenous leiomyomatosis and intravenous leiomyosarcomatosis.
Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis.